• Explore /
  • Poster
  • / PSMAfore: A phase 3 study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.

PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

A. Sartor

A. Oliver Sartor

School of Medicine, Tulane Medical School, New Orleans, LA

A. Oliver Sartor , Michael J. Morris , Kim N. Chi , Johann S. De Bono , Neal D. Shore , Michael Crosby , Teri Nguyen Kreisl , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04689828

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS211)

DOI

10.1200/JCO.2022.40.6_suppl.TPS211

Abstract #

TPS211

Poster Bd #

Q10

Abstract Disclosures

Similar Posters

First Author: Simon J. Crabb

First Author: Kambiz Rahbar

First Author: Louise Emmett

First Author: Neeraj Agarwal